RussellEbertHandball
Flick pass expert
I reckon the first thing that will be released by pharmaceutical companies is a virus suppressant like you have with HIV and Hepatitis C. We haven't found a vaccine for them but one pharmaceutical company Gilead Science makes the drug that has suppressed both those diseases killing people in large numbers. Dr Norman Swan spoke about this last night on 7.30.So what if a vaccine doesn't arrive or can't be produced? Hinging the future solely on a vaccine is a recipe for disaster. Even without a vaccine, it must be noted that to date, over 492k people have beaten the virus, whilst of the 1.4 million current active cases, 1.35 million have a mild condition.
To assume anything regarding sporting matches right now is to predict too far into the future. Though I would note that just one week prior to going into lockdown, the women's world T20 final had 84k people at the G, and we saw no issues stemming from that event.
Thats not to say sporting events should be populated right now, but rather that it will be possible even without a vaccine, for sporting events to be populated by fans down the line. I would be surprised if fans don't have access to attending games by the end of the year, but it will be interesting to see how it all develops regardless.
7.30
www.abc.net.au
DR NORMAN SWAN: And there's another serious issue with hydroxychloroquine.
Here's what happens electrically in the heart when it beats. Each electrical wave has a letter - P, Q, R, S and T. The distance between the Q wave and the T wave is critical for controlling how safely the heart beats. People with severe COVID-19 can have a long QT interval which puts them at peril of fatal heart rhythms. Hydroxychloroquine makes the QT interval even longer.
There's an enormous range of treatments being suggested for COVID-19 from hydroxychloroquine to blood pressure drugs to SheepIT.
There are broadly three approaches to treatment.
One is to dampen the life-threatening immune overreaction.
The second is to try to strengthen our resistance to the virus, that's the SheepIT angle, that drug is called Ivermectin.
And the third is to find a drug which kills the virus or stops it multiplying.
The front-runner in that race is a drug made by the pharmaceutical company Gilead, which has made a fortune for its sweep of antiviral drugs for HIV and Hepatitis C.
The COVID-19 candidate is called remdesivir.
MEG TIRRELL, CNBC BUSINESS NEWS: ...an update on 53 patients who had received remdesivir under what is called "compassionate use."
DR PAUL SLADE, SENIOR MEDICAL DIRECTOR, GILEAD: Basically, it prevents the virus making copies of its own genetic material and as a result then the virus can't replicate, it can't then infect more human cells. It stops that. The replication of the virus.
DR NORMAN SWAN: This is the holy grail in antivirals. Namely a drug that can treat more than one virus. However, when they tried remdesivir in Ebola it didn't work.
So, why think of it for this novel coronavirus?
DR PAUL SLADE: We know that it works - as I say, in the laboratory against other members of the same family of viruses as this coronavirus. So we believe, especially in this time of a pandemic health crisis, that it's worth exploring whether it has activity against COVID-19.
DR NORMAN SWAN: Gilead is taking a more traditional approach to testing remdesivir by using randomised control trials in hospitalised patients who receive the medication intravenously.
DR PAUL SLADE: So, there are multiple studies ongoing. We have two studies of our own. China had two studies ongoing since pretty much the start of their pandemic. There are two other studies being run both in the US and Europe. We are hopeful that we will have some initial data by the end of April.
DR NORMAN SWAN: The World Health Organisation has launched a global crowdfunding effort to fund trials of hydroxychloroquine and remdesivir, along with other medications. WHO hopes this will accelerate findings which will tell whether these drugs work.
HOLLY FERNANDEZ LYNCH: In the state of pandemic, we really, really have to hang on to our scientific principles of rigorous controlled clinical trials and we can't abandon those scientific principles on the assumption that we don't have time to wait.